PCORI allocates $42M for new research

The projects will delve into palliative care, depression, asthma, pediatric cancer as well as patient-centered outcomes.
By Bernie Monegain
11:24 AM

The Patient-Centered Outcomes Research Institute Board of Governors has approved nearly $42 million to fund 19 new studies.

The work will compare which healthcare approaches work best in treating a wide range of conditions and problems that affect patients, caregivers and the healthcare system.

PCORI said the new projects include: $6 million to compare the effectiveness of two types of palliative care, $3 million to determine the impact of different health plans on medication use and outcomes for patients with asthma, $2.7 million to determine the effect of acupressure on relieving treatment-related symptoms in children with cancer, and $2.3 million toward determine whether established treatment or a newer drug is more effective against treatment-resistant cases of Kawasaki disease.

Another six projects will study ways to improve methods for conducting patient-centered outcomes research. Among them is work assessing the quality of communications between healthcare providers and patients, preserving patient privacy when data sets including medical information are linked, and measuring patients’ preferences.

“We are pleased to add this latest round of projects to our portfolio of patient-centered research,” PCORI Executive Director Joe Selby, MD, said in a statement.

Including these latest awards, PCORI’s Board has approved about $1.6 billion since 2012 to fund 570 patient-centered CER studies and other projects to enhance the methods and infrastructure to support CER.

PCORI is an independent, nonprofit organization authorized by Congress in 2010.

Twitter: @Bernie_HITN
Email the writer: bernie.monegain@himssmedia.com

Like Healthcare IT News on Facebook and LinkedIn

Want to get more stories like this one? Get daily news updates from Healthcare IT News.
Your subscription has been saved.
Something went wrong. Please try again.